Andrew A. Davis

ORCID: 0000-0003-3663-2133
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cancer Genomics and Diagnostics
  • Advanced Breast Cancer Therapies
  • Lung Cancer Treatments and Mutations
  • Cancer Cells and Metastasis
  • Genetic factors in colorectal cancer
  • HER2/EGFR in Cancer Research
  • Breast Cancer Treatment Studies
  • Cancer Treatment and Pharmacology
  • Cancer Immunotherapy and Biomarkers
  • BRCA gene mutations in cancer
  • Lung Cancer Research Studies
  • Epigenetics and DNA Methylation
  • Colorectal Cancer Treatments and Studies
  • Ferroptosis and cancer prognosis
  • Radiomics and Machine Learning in Medical Imaging
  • Cancer Diagnosis and Treatment
  • Lung Cancer Diagnosis and Treatment
  • Transplantation: Methods and Outcomes
  • Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Pancreatic and Hepatic Oncology Research
  • Renal Transplantation Outcomes and Treatments
  • Neural and Behavioral Psychology Studies
  • Neurogenesis and neuroplasticity mechanisms
  • Molecular Biology Techniques and Applications
  • Cancer-related molecular mechanisms research

Washington University in St. Louis
2020-2025

Northwestern University
2014-2023

Discovery Institute
2023

Sanford Burnham Prebys Medical Discovery Institute
2023

La Jolla Institute for Immunology
2023

Institute of Immunology
2023

Massachusetts Institute of Technology
2022

American Society of Hematology
2022

University of Nebraska Medical Center
2022

Whitehead Institute for Biomedical Research
2022

The development of immune checkpoint inhibitors has changed the treatment paradigm for advanced cancers across many tumor types. Despite encouraging and sometimes durable responses in a subset patients, most patients do not respond. Tumors have adopted PD-1/PD-L1 axis escape to facilitate growth, which can be leveraged as potential target inhibitors. On this basis, PD-L1 protein expression on or cells emerged first predictive biomarker sensitivity blockade. goal our study was evaluate based...

10.1186/s40425-019-0768-9 article EN cc-by Journal for ImmunoTherapy of Cancer 2019-10-26

Journal Article Philosophy of Mathematics Education Get access Andrew Davis Correspondence: Davis, School Education, Leazes Road, University Durham, Durham DH1 1TA, United Kingdom. Search for other works by this author on: Oxford Academic Google Scholar Volume 26, Issue 1, July 1992, Pages 121–126, https://doi.org/10.1111/j.1467-9752.1992.tb00272.x Published: 30 May 2006

10.1111/j.1467-9752.1992.tb00272.x article EN Journal of Philosophy of Education 1992-07-01

Abstract While identifying genomic alterations in tumor tissue is the current gold-standard technique for molecular profiling, circulating DNA (ctDNA) represents a noninvasive method of assessing using peripheral blood. The concordance between two commercially available ctDNA and biopsies was compared 45 patients with breast cancer paired next-generation sequencing biopsies. Across all genes, platforms 91.0% to 94.2%. When only considering either assay (e.g., excluding wild type/wild type...

10.1158/1535-7163.mct-17-0061 article EN Molecular Cancer Therapeutics 2017-04-27

Allograft failure is common in lung-transplant recipients and leads to poor outcomes including early death. No reliable clinical tools exist identify patients at high risk for allograft failure. This study tested the use of donor-derived cell-free DNA (%ddcfDNA) as a sensitive marker graft injury predict impending failure.This multicenter, prospective cohort enrolled 106 subjects who underwent lung transplantation monitored them after development (defined severe chronic dysfunction [CLAD],...

10.1016/j.ebiom.2018.12.029 article EN cc-by-nc-nd EBioMedicine 2019-01-27

Genomic analysis of tumor tissue is the standard technique for identifying DNA alterations in malignancies. circulating cell-free (cfDNA) represents a relatively non-invasive method assessing genomic using peripheral blood. We compared concordance between cfDNA and biopsies this retrospective study. Twenty-eight patients with advanced solid tumors paired next-generation sequencing were identified. Sixty-five genes common to both assays. Concordance was defined as presence or absence...

10.18632/oncotarget.11692 article EN Oncotarget 2016-08-30

Abstract The bed nucleus of the stria terminalis (BNST), a portion “extended amygdala,” is implicated in pathophysiology anxiety and addiction disorders. Its small size connection to other regions prevents standard imaging techniques from easily capturing it its connectivity with confidence. Seed‐based resting state functional an established method for mapping connections across brain region interest. We, therefore, mapped BNST network high spatial resolution using 7 Tesla fMRI,...

10.1002/hbm.22899 article EN Human Brain Mapping 2015-07-14

Tissue tumor mutational burden (TMB) has emerged as a potential biomarker predicting response to anti-programmed cell death-1 protein receptor (PD-1)/programmed ligand (PD-L1) therapy, but few studies have explored using circulating DNA (ctDNA) TMB in non-small lung cancer (NSCLC).A total of 136 patients with NSCLC ctDNA testing were retrospectively evaluated from single institution, along validation cohort second institution. was derived the number detected mutations over sequencing...

10.1634/theoncologist.2018-0433 article EN The Oncologist 2019-03-13

Abstract Purpose: Clinical biomarkers to identify patients unlikely benefit from CDK4/6 inhibition (CDK4/6i) in combination with endocrine therapy (ET) are lacking. We implemented a comprehensive circulating tumor DNA (ctDNA) analysis genomic features for predicting and monitoring treatment resistance. Experimental Design: ctDNA was isolated 216 plasma samples collected 51 hormone receptor–positive (HR+)/HER2-negative (HER2−) metastatic breast cancer (MBC) on phase II trial of palbociclib...

10.1158/1078-0432.ccr-22-2177 article EN cc-by-nc-nd Clinical Cancer Research 2023-01-24

Abstract Purpose: Clinical tools to monitor treatment response and metastatic risk could improve early-stage triple-negative breast cancer (TNBC) care. While molecular residual disease (MRD) assays show promise, their use in the neoadjuvant setting requires rapid turnaround times. Tissue-informed approaches may be challenging for patients with limited biopsy samples. The objectives were determine surveillance sensitivity detecting recurrence evaluate ctDNA therapy using a tissue-free...

10.1158/1078-0432.ccr-24-3145 article EN Clinical Cancer Research 2025-03-21

We describe the genomic landscape of circulating tumour DNA (ctDNA) across pathological subtypes metastatic breast cancer.

10.1016/j.ebiom.2020.102914 article EN cc-by-nc-nd EBioMedicine 2020-07-21

ABSTRACT Ventricular zone cells in the developing CNS undergo extensive cell division vivo and under certain conditions vitro. The culture that promote have been studied to determine role contact with membrane associated factors plays proliferation of these cells. Progenitor taken from ventricular rat cerebral cortex placed into microwells. Small clusters can generate large numbers neurons non-neuronal progeny. In contrast, single progenitor largely cease division, approximately 90%...

10.1242/dev.120.4.999 article EN Development 1994-04-01

Abstract Purpose Liquid biopsies, including circulating tumor DNA (ctDNA) and cells (CTCs), can be used to understand disease prognosis, heterogeneity, dynamic response treatment in metastatic breast cancer (MBC). We explored a novel, 180-gene ctDNA panel the association of this platform with CTCs CTC clusters. Methods A total 40 samples from 22 patients MBC were included study. For primary analysis, all had sequencing using PredicinePLUS™ platform. clusters examined CellSearch™ System....

10.1186/s13058-019-1229-6 article EN cc-by Breast Cancer Research 2019-12-01

Liquid biopsy provides real-time data about prognosis and actionable mutations in metastatic breast cancer (MBC). The aim of this study was to explore the combination circulating tumour DNA (ctDNA) analysis cells (CTCs) enumeration estimating target organs more susceptible MBC involvement.This retrospective analysed 88 patients characterised for both CTCs ctDNA at baseline. were isolated through CellSearch kit, while using Guardant360 NGS-based assay. Sites disease collected on basis...

10.1016/j.ejca.2020.11.005 article EN cc-by-nc-nd European Journal of Cancer 2020-12-09

Abstract Purpose: Circulating tumor DNA (ctDNA) is a promising tool for noninvasive longitudinal monitoring of genomic alterations. We analyzed serial ctDNA to characterize evolution in progressive metastatic breast cancer. Experimental Design: This was retrospective cohort between 2015 and 2019 obtained under an Institutional Review Board–approved protocol at Northwestern University (Chicago, IL). samples were with Guardant360 next-generation sequencing (NGS) assay. A total 86 patients had...

10.1158/1078-0432.ccr-20-1566 article EN Clinical Cancer Research 2021-01-25

This study investigates symptom presentation and school functioning in a nonclinical sample of children with social phobia (SP). Forty-five SP were identified via school-wide screenings follow-up diagnostic interviews. Analyses examined types intensity fears, number situations avoided, interpersonal relationships, classroom functioning. To identify characteristics unique to phobic children, (n = 45) compared anxious without 56) on the above variables. Comorbidity factors associated severity...

10.1002/da.20315 article EN Depression and Anxiety 2007-06-07
Coming Soon ...